In Print
“All she needs is approval from the president to tap into that basket,” Henrietta Treyz, director of economic policy research at Veda Partners, said of Ms. Yellen. “There are no other alternatives; there’s no chance of a bill passing Congress.”
— Henrietta Treyz, New York Times
By dropping the cost of its Humalog and Humulin insulins, Lilly could sidestep $430 million per year in new Medicaid rebates and make more than $85 million in new annual profit, according to an analysis by Spencer Perlman, the director of healthcare research at Veda Partners.
— Spencer Perlman
“The biggest issue here is just the lack of clarity on what’s coming and what it means,” Perlman said in an interview. His analysis draws from government data and reporting from Kaiser Health News. Veda, a Bethesda, Maryland-based policy research firm that doesn’t make stock recommendations, estimated what plans might pay if the proposed rule was finalized without changes.
— Spencer Perlman
"There is something deeply ironic about Donald Trump potentially returning to power and implementing the price reductions on something where he went out on a limb for Republicans," Spencer Perlman, director of healthcare research at Veda Partners, an investment advisor, and consultancy firm, told Insider.
— Spencer Perlman
““It gives a chance for these hospitals to exist,” said Spencer Perlman, director of healthcare research at Veda Partners. “It’s a choice between what you have now and nothing.” Perlman estimates hospitals could receive around $750,000 in additional funding under the program, on average, adding the amount could vary widely depending upon how CMS calculates payments.”
— Spencer Perlman, Bloomberg
““Competition policy and antitrust reform is the likeliest potential legislation affecting the tech sector that this Congress could pass, and yet I still think it’s below 50% odds,” said Alex Cynamon, a policy analyst with research firm Veda Partners. “It’s a tall order for any advocates and groups to compel Congress to actually enact material changes to the statute.””
— Alex Cynamon in WSJ
“Alex Cynamon, an analyst at Veda Partners, told MarketWatch that while these lines of attack were not wholly new, and that often Republican and Democratic complaints about Big Tech practices were at odds with one another, investors should be concerned with what he saw was a new interest on the part of lawmakers on the “core business models of targeted, behavioral advertising” by social media companies.”
— Alex Cynamon in Marketwatch
“Though this rhetoric has not so far led to Republicans taking the plunge into serious legislative action, it could provide the political cover for the Federal Trade Commission to redefine its relationship to competition policy, according to Alex Cynamon of Veda Partners. “There’s a level of bipartisan support that should embolden the Biden administration to pursue enforcement actions and rule making that address competition policy and could even be narrowly focused on the tech sector,” he said.”
— Alex Cynamon in Marketwatch
“Imagine what the 2020 election would be about without the trade war, or threats to tariff Mexico over immigration policy. The incumbent president stands to win a reelection with the two issues raging into 2020 — even with some modest economic hit — and may not otherwise.”
— Henrietta Treyz in MarketWatch
“But Spencer Perlman, managing partner and director of health care research at Veda Partners in Bethesda, Md., said Medicare for All would prohibit private entities from duplicating government programs... “It would legislate out of existence” private insurers, he said.”
— Spencer Perlman, Hartford Courant
“Veda Partners health care policy analyst Spencer Perlman called the DOJ’s about face “a stunning and politically tone-deaf move.” The most likely scenario is that the law stays as it is, with a 5 percent chance that it’s struck down, according to Perlman.”
— Spencer Perlman, Bloomberg
“The hearing will absolutely be a free-for-all with a robust discussion of capitalism vs. socialism”
— Henrietta Treyz, MarketWatch
“Lighthizer offers a far more grounded prognosis of the likelihood of success than President Trump and others in the administration recently have,” said Henrietta Treyz, director of economic policy at the investment advisory firm Veda Partners. “Without fail, Lighthizer makes sure to acknowledge that failure and success are both options with China.””
— Henrietta Treyz, New York Times
“The street very much wants to see the tariffs come off...but folks in DC trade circles and those familiar with the talks indicate that at best we probably see a small piece of the tariffs will come off, not nearly the overarching basket that the street is looking for.”
— Henrietta Treyz, Bloomberg
“Trade is likely to occupy “a substantial portion” of the speech, as legislative action from Congress during the next two years is unlikely, so Trump needs to prioritize “areas where he can enact change unilaterally,” Veda Partners director of economic policy research Henrietta Treyz says. She expects Trump to “leave the door open for further tariffs ... but message that progress is being made.””
— Felice Maranz, Bloomberg
“Henrietta Treyz, director of economic policy research at the investment advisory firm Veda Partners, spent her weekend studying the 1935 Banking Act to determine whether Mr. Trump could unseat Mr. Powell as chairman but keep him on the Fed board without violating the law. She has yet to determine whether that could pass legal muster.”
— Alan Rappeport, New York Times
“We do not have evidence to suggest that China is preparing to capitulate in such a manner and do not see an end to the tariffs in the near term.”
— Henrietta Treyz, New York Times
“They are trying to thread the needle on all three of those [trading] issues so it’s definitely an uphill battle”
— Henrietta Treyz
“Trade talks are occurring outside of any [traditional] economic conversation...the metric is GDP growth, wages, unemployment, and until those things start to shift, you’re not going to see any efforts from the republican caucus in any earnest way to reign this in.”
— Henrietta Treyz
“Companies have money overseas, “but there is tremendous uncertainty in the market, painfully slow economic growth and I believe corporations want certainty on a far more global scale than anything capital expensing can provide them”
— Henrietta Treyz
“My expectation for investors is that we’ll keep this to a top of about 22 and a half if it even rises above 20 percent.”
— Henrietta Treyz
“This was purposely opaque,” said Henrietta Treyz, director of economic policy and a managing partner at Veda Partners. “They are under strong pressure from multinationals to make sure that they don’t get hit hard.”
— Henrietta Treyz
“I see them putting these ideas out as though they’re making progress, but they are the same regurgitated ideas we’ve been talking about for 20 years that have never gotten past the white-paper stage.”
— Henrietta Treyz
“The goal for the Republicans will be to come
back with a clean slate on October 1st.”
— Henrietta Treyz
“The doors are open for financial services and insurers to negotiate with policy makers in the House to ease into this, as they know that removing the net interest deduction is particularly onerous,”
— Henrietta Treyz
“By referencing foreign taxes on American exports, Trump “came within striking distance of supporting” Ryan’s plan for border adjustments”
— Henrietta Treyz
“I definitely noticed the shift toward the end of last year of an increasing interest in looking at hospital pricing.” “Once that shift happens, it’s hard to put the genie back in the bottle — the issue is here to stay.” “The question is how long can AHA stave it off? And I think they can for a long period of time.”
— Spencer Perlman
"Severing the link between fees and drug prices “is probably the most significant thing” Congress could do to change how PBMs operate. Lawmakers are always playing whack-a-mole, and they’re always a little bit behind.”
— Spencer Perlman
Henrietta Treyz, director of economic policy research at Veda Partners, is no stranger to deciphering Washington, D.C., for investors. And there is a lot to decipher these days, what with two wars, a massive buildup of government debt, a congressional spending fight, and the nomination of Sen. Steve Scalise (R., La.) to replace ousted House of Representatives Speaker Kevin McCarthy (D., Calif.).
Henrietta Treyz of Veda Partners sees an 80% chance of a partial US government shutdown https://trib.al/N4VWkSs
"We're going to have a debt crisis in this country," billionaire investor Ray Dalio said during an interview at a recent event in New York organized by the Managed Funds Association.
“DeSantis did the most good for his campaign tonight and NewsNation is unquestionably the big winner. By far the best debate because the moderators actually asked about issues that the Republican base care about,”
— Megan Basham, New York Times
“Sanofi is joining the nation’s two other major insulin manufacturers in offering either price caps or savings programs that lower the cost of the drugs to $35 for many patients. The three drugmakers are also drastically lowering the list prices for their products.”
— Tami Luhby, CNN
“By draining each fund down to $0 lawmakers have ensured they will have no easy offsets available to pay for the panoply of reforms and fixes that must be addressed at year-end. Thus, we think that lawmakers must incorporate both PBM reforms and site neutral adjustments into whatever legislative package emerges at year-end.”
— Spencer Perlman
Monday’s rate announcement follows a series of incremental changes — from new rules on marketing to changes in arcane billing systems — that have “holistically reformed” the Medicare Advantage program over the past three years, said Spencer Perlman, an analyst at policy researcher Veda Partners. While there was no single policy overhaul, the incremental changes add up.
“We’re starting to see that reflected in some of the stock prices,” he said in an interview Tuesday.
Video & Audio Appearances
Live on Bloomberg
Henrietta Treyz Previews the Biden-Johnson Meeting
Live on Bloomberg
Veda Partners' Treyz on McCarthy's Future
“There are some small things on the margins that the administration can do without congress... one of the things specifically would be to institute investment restrictions...”
— Henrietta Treyz on Bloomberg Surveillance Podcast
“Amongst the Republican party you've got roughly 80% approval for the President's trade agenda... and that's what's driving them”
— Henrietta Treyz on Bloomberg Surveillance Podcast
“My concern is that the Chinese have been working on how they are going to retaliate to our uptick in tariffs more than they've been working on how to correct the 150 pages worth of adjustments that they want to see in the deal that Lighthizer has written up”
— Henrietta Treyz on Bloomberg Surveillance Podcast
“All of the trade wars are so heavily about optics, especially in China”
— Henrietta Treyz on Bloomberg Surveillance Podcast
“If you come to China understanding that they view the 2018 elections as a referendum against President Trump.. you get the sense that not just China, but also Japan, and the European Union are just stalling for time”
— Henrietta Treyz on Bloomberg Surveillance Podcast
“Henrietta Treyz, Veda Partners Director of Economic Policy, recommends stacking up on avocados, in the case that the U.S increases tariffs on Mexico”
— Henrietta Treyz on Bloomberg Surveillance Podcast
According to Sources Podcast
Henrietta Treyz Discusses China & Trade on According to Sources
Henrietta Treyz on Yellen Warning
Henrietta Treyz, Managing Partner and Director of Economic Policy at Veda Partners discusses Treasury Secretary Yellen's warning to Congress. She spoke with hosts Bryan Curtis and Paul Allen on Bloomberg Radio.
